PhRMA, friends air $12m pro-reform TV spot

Share this article:
PhRMA, friends air $12m pro-reform TV spot
PhRMA, friends air $12m pro-reform TV spot
The first execution in PhRMA's promised pro-health reform campaign drops today. The 30-second TV spot, dubbed “Mean for you,” emphasizes the impact of proposed legislation on individuals.

“What does health insurance reform mean for you?” the narrator asks, amid warm piano music and images of hospital patients and staff. “It means you can't be denied coverage for a pre-existing condition or dropped if you get sick.”

The ad, though primarily funded by PhRMA, is the work of a coalition including the AMA and the Federation of American Hospitals as well as liberal advocacy group Families USA and the service employees' union SEIU. It will run through early September at a cost of around $12 million and was produced by DC ad shop GMMB, a White House favorite. It will be followed by print ads, starting next week, as well as radio.

PhRMA SVP Ken Johnson said the spot is the first of a wave of new ads the organization is airing, some of which will be aimed at fostering general awareness, others more issue-specific. “We will have additional commercials ready to go in the next week or so,” said Johnson. “They will be strategically targeted around the country where we believe we can make a difference.”

Not all advertising will be done through the coalition, called Americans for Stable Quality Care. Some will be PhRMA-branded, others jointly sponsored by PhRMA and Families USA, Johnson said. A “mix” of agencies is working on the ads.

GMMB produced an earlier iteration of the campaign that aired in January with the message that healthcare reform is essential to getting the economy back on track. That spot was sponsored by a similar coalition.

“Mean for you” is airing in 12 states represented by congressional centrists. “There's a lot of criticism right now that the process is moving too quickly,” said Johnson. “Opponents of reform say ‘Slow down, let's take the time to think it through.' Those are all delaying tactics designed to kill reform, and our argument is that it can't wait anymore.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...